Debora Soncini

Genoa, 16132, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Journal: Cancers
Published: April 14, 2026

The immunosuppressive role of HLA-G+ extracellular vesicles in bone marrow of infiltrating tumors: the lesson learned from neuroblastoma and multiple myeloma.

The immunosuppressive role of HLA-G+ extracellular vesicles in bone marrow of infiltrating tumors: the lesson learned from neuroblastoma and multiple myeloma.

Journal: Human immunology
Published: November 28, 2025

CRISPR application in hematological disorders: from bench to bedside.

CRISPR application in hematological disorders: from bench to bedside.

Journal: Blood advances
Published: September 10, 2025

Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1.

Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1.

Journal: Frontiers in immunology
Published: June 03, 2025

Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies.

Monoclonal gammopathy of renal significance (MGRS): retrospective monocentric analysis of clinical outcomes and treatment strategies.

Journal: Clinical and experimental medicine
Published: February 27, 2025

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.

Journal: Scientific reports
Published: August 17, 2024

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

Journal: Blood cancer journal
Published: June 14, 2024

NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.

NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.

Journal: Blood advances
Published: April 17, 2024

Sirtuin 6 Regulates the Activation of the ATP/Purinergic Axis in Endothelial Cells.

Sirtuin 6 Regulates the Activation of the ATP/Purinergic Axis in Endothelial Cells.

Journal: International journal of molecular sciences
Published: February 27, 2023

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents.

CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents.

Journal: Antioxidants (Basel, Switzerland)
Published: December 28, 2022

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis.

Journal: Blood
Published: December 05, 2022

Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma.

Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma.

Journal: Blood advances
Published: September 28, 2022
Showing 1-12 of 29

Last Updated: 09/26/2026